Steven Gillis

Steven Gillis is a Managing Director with ARCH, joining the firm as a Venture Partner in 2005. Steven is focused on the evaluation of new life science technologies and also on the development and growth of ARCH's biotechnology portfolio companies. Steven is a Member of the Board of Directors at Homology Medicines, Inc., Allozyne, Pulmatrix (PULM), Codiak Biosciences, Faraday Pharmaceuticals, Just. Biotherapeutics, VLST, Lodo Therapeutics and Accelerator. Steven serves as Member of the Board of Directors and Chairman of the Board of Directors at VentiRx Pharmaceuticals, Theraclone Sciences, Lycera, VBI Vaccines (VBIV) and PhaseRx. Steven was a Founder and a Member of the Board of Directors at Corixa Corp. and served as Chief Executive Officer from its inception and as its Chairman of the Board of Directors from 1999 until its acquisition in 2005 by GlaxoSmithKline. Prior to Corixa, Stevens was a Founder and Member of the Board of Directors at Immunex Corp., the most successful venture-funded biotech company in the state of Washington. From 1981 until his departure in 1994, Steven served as Immunex's Director of Research and Development, Chief Scientific Officer and as Chief Executive Officer of Immunex's R&D subsidiary. Steven was interim Chief Executive Officer of Immunex Corp. following its majority purchase by American Cyanamid Co. and remained a Member of the Board of Directors until 1997. Amgen, Inc. acquired Immunex in 2002. Steven is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. Steven is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20). Steven received a B.A. degree from Williams College and a Ph.D. from Dartmouth College.